Financials data is unavailable for this security.
View more
Year on year Amneal Pharmaceuticals Inc grew revenues 8.20% from 2.21bn to 2.39bn while net income improved from a loss of 129.99m to a smaller loss of 83.99m.
Gross margin | 35.34% |
---|---|
Net profit margin | -5.46% |
Operating margin | 7.00% |
Return on assets | -4.10% |
---|---|
Return on equity | -155.38% |
Return on investment | -5.45% |
More ▼
Cash flow in USDView more
In 2023, Amneal Pharmaceuticals Inc increased its cash reserves by 181.34%, or 63.88m. The company earned 345.58m from its operations for a Cash Flow Margin of 14.44%. In addition the company used 69.19m on investing activities and also paid 212.57m in financing cash flows.
Cash flow per share | 0.2729 |
---|---|
Price/Cash flow per share | 31.99 |
Book value per share | -0.3016 |
---|---|
Tangible book value per share | -4.75 |
More ▼
Balance sheet in USDView more
Current ratio | 1.38 |
---|---|
Quick ratio | 0.8372 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | 1.01 |
More ▼